CN116672309A - 干混悬药物组合物 - Google Patents
干混悬药物组合物 Download PDFInfo
- Publication number
- CN116672309A CN116672309A CN202310923783.XA CN202310923783A CN116672309A CN 116672309 A CN116672309 A CN 116672309A CN 202310923783 A CN202310923783 A CN 202310923783A CN 116672309 A CN116672309 A CN 116672309A
- Authority
- CN
- China
- Prior art keywords
- dry suspension
- pharmaceutical composition
- suspension pharmaceutical
- composition according
- linaclotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims abstract description 28
- 229960000308 fosfomycin Drugs 0.000 claims abstract description 28
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 claims abstract description 25
- 108010024409 linaclotide Proteins 0.000 claims abstract description 25
- 229960000812 linaclotide Drugs 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 239000003086 colorant Substances 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 7
- 239000003381 stabilizer Substances 0.000 claims abstract description 7
- 239000000375 suspending agent Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims description 23
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000004806 packaging method and process Methods 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 235000010356 sorbitol Nutrition 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000004376 Sucralose Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- 235000011083 sodium citrates Nutrition 0.000 claims description 7
- 235000019408 sucralose Nutrition 0.000 claims description 7
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 7
- 239000004408 titanium dioxide Substances 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 7
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- 235000010493 xanthan gum Nutrition 0.000 claims description 7
- 229940082509 xanthan gum Drugs 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 239000011812 mixed powder Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 229920002785 Croscarmellose sodium Chemical class 0.000 claims description 3
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 2
- 240000002319 Citrus sinensis Species 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000018342 monosodium citrate Nutrition 0.000 claims description 2
- 239000002524 monosodium citrate Substances 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Chemical class 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 239000011734 sodium Chemical class 0.000 claims description 2
- 229910052708 sodium Chemical class 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- 229960001790 sodium citrate Drugs 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 12
- 206010010774 Constipation Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960005196 titanium dioxide Drugs 0.000 description 3
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 102000000820 Enterotoxin Receptors Human genes 0.000 description 2
- 108010001687 Enterotoxin Receptors Proteins 0.000 description 2
- 241000220223 Fragaria Species 0.000 description 2
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 2
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 2
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010085193 UDP-N-acetylglucosamine 1-carboxyvinyltransferase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-VKHMYHEASA-N sn-glycerol 1-phosphate Chemical compound OC[C@H](O)COP(O)(O)=O AWUCVROLDVIAJX-VKHMYHEASA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- PKIDNTKRVKSLDB-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate Chemical compound O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PKIDNTKRVKSLDB-UHFFFAOYSA-K 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种干混悬药物组合物。由如下重量百分比的组分构成：利那洛肽0.005‑0.02%、磷霉素氨丁三醇30‑60%、填充剂30‑60%、助悬剂0.5‑2.0%、崩解剂0.5‑3.0%、稳定剂0.3‑1.5%、矫味剂0.02‑2.0%、着色剂0.5‑3.0%、pH调节剂0.1‑3.0%。本发明制备的干混悬组合物比单方制剂具有更好的发挥治疗便秘的效果，发明人所研制的干混悬组合物填补了市场空白，给患者提供了新的治疗选择，且方便了患者用药，提高患者用药的顺从性。
Description
技术领域
本发明属于便秘治疗的药物组合物技术领域，具体涉及一种干混悬药物组合物。
背景技术
利那洛肽是一种鸟苷酸环化酶-C（GC-C）受体激动剂。在腔内发现GC-C受体大脑中肠上皮和多巴胺神经元的一个方面，是热稳定肠毒素的关键受体，其导致急性分泌性腹泻。利那洛肽在结构上与鸟苷肽家族有关，其与肠液体内稳态和肠道的调节有关。利那洛肽，类似于鸟苷素和尿鸟苷素，能够增加第二信使环鸟苷的细胞内浓度单磷酸（cGMP）通过激活GC-C受体，位于顶端表面整个肠道的上皮细胞。细胞内cGMP的存在触发信号转导级联导致囊性纤维化跨膜传导的激活调节因子（CFTR）通过其蛋白激酶G II（PKG II）的cGMP依赖性磷酸化。CFTR激活导致氯离子和碳酸氢盐分泌到肠腔中，导致液体分泌增加和胃肠道转运加速。cGMP也被运出细胞进入肠腔和粘膜下层，调节局部传入神经纤维的活动并导致减少内脏痛。利那洛肽口服时，给予125mcg或290mcg剂量后，未观察到可检测水平的利那洛肽或其活性代谢物。代谢利那洛肽在胃肠道内通过失去末端酪氨酸部分被代谢为其主要活性代谢物MM-419447。利那洛肽和代谢物在肠腔内被蛋白水解降解为较小的肽和天然存在的氨基酸。
磷霉素通过与UDP-N-乙酰葡糖胺烯醇丙酮酰转移酶（MurA）酶活性位点的半胱氨酸共价结合，使其失活来发挥其杀菌作用。通过阻止MurA催化磷酸烯醇丙酮酸（PEP）与UDP-N-乙酰葡糖胺（UNAG）的缩合，磷霉素抑制肽聚糖前体UDPN-乙酰胞壁酸（UDP-MurNAc）的产生。最终，细菌细胞壁合成的第一步被破坏。在大肠杆菌中，磷霉素通过两种机制进入细菌细胞：L-α-甘油磷酸系统和己糖-6-磷酸转运系统。1个磷霉素对细胞粘附也有重要影响。例如，在磷霉素的存在下，细菌细胞与尿道上皮细胞的粘附减少。肺炎链球菌和流感嗜血杆菌对呼吸道上皮细胞的粘附也减少。
磷霉素是一种低分子量亲水性药物。当口服给药时，磷霉素在小肠中迅速吸收并广泛分布到组织中。口服生物利用度范围为34-58%。磷霉素与食物同时给药会使胃肠道吸收减少约30%。AUC=145-228mgxh/L，Cmax=26.1（±91）mcg/mL。分布容积，磷霉素在健康受试者中，磷霉素的分布容积（Vd）约为0.3L/Kg。由于血管内皮细胞的变化，重症患者的Vd可高达50%。磷霉素的平均消除半衰期为5.7（±2.8）小时。磷霉素不被代谢，主要以原形从尿中排出。
发明内容
本发明的目的在于提供一种治疗便秘药物组合物，尤其适治疗肠易激综合征伴便秘（IBS-C）和慢性特发性便秘（CIC）。
本发明另一方面，提供制备干混悬药物组合物的方法以及使用所述干混悬组合物治疗便秘的方法。
一种干混悬药物组合物，由如下重量百分比的组分构成：利那洛肽0.005-0.02%、磷霉素氨丁三醇30-60%、填充剂30-60%、助悬剂0.5-2.0%、崩解剂0.5-3.0%、稳定剂0.3-1.5%、矫味剂0.02-2.0%、着色剂0.5-3.0%、pH调节剂0.1-3.0%。
所述填充剂为乳糖、甘露醇、麦芽糖醇、山梨醇、淀粉水解寡糖中的一种或几种。
所述助悬剂为黄原胶、聚乙烯吡咯烷酮、羧甲基纤维素钠、明胶、羟丙基纤维素、羟丙甲基纤维素中的一种或几种。
所述崩解剂为低取代的羟丙甲基纤维素、交联羧甲基纤维素钠、交联聚维酮、羧甲基淀粉钠中的一种或几种。
所述稳定剂为亮氨酸、甲硫氨酸、氯化钙、精氨酸中的一种或几种。
所述矫味剂为甜味剂和/或芳香剂；甜味剂为阿斯巴甜、甜菊糖苷、糖精、糖精钠、三氯蔗糖中一种或几种；芳香剂为甜橙香精、柠檬香精、橘子香精、草莓香精中一种或几种。
所述着色剂为二氧化钛。
所述pH调节剂为柠檬酸、柠檬酸钠、一水合柠檬酸、柠檬酸二氢钠中的一种或几种。
所述干混悬药物组合物的制备方法，按照如下步骤进行：
（1）将原料分别粉碎过80-160目筛；
（2）将利那洛肽、磷霉素氨丁三醇、填充剂、助悬剂、崩解剂、稳定剂、pH调节剂、着色剂采用等量递加的方式，混合均匀，得混和粉末；
（3）取步骤（2）制得的混和粉末与矫味剂混合，包装，制成。
本发明的有益效果：本发明制备的干混悬组合物比单方制剂具有更好的发挥治疗便秘的效果。发明人所研制的干混悬组合物填补了市场空白，给患者提供了新的治疗选择，且方便了患者用药，提高患者用药的顺从性。
具体实施方式
为了便于理解本发明，下面将对本发明进行更全面的描述。但是，本发明可以以许多不同的形式来实现，并不限于本文所描述的实施例。相反地，提供这些实施例的目的是使对本发明的公开内容的理解更加透彻全面。
实施例1
干混悬剂由如下重量百分比的物质组成：
制备方法：将利那洛肽和磷霉素氨丁三醇粉碎过100目筛；利那洛肽和山梨醇等量递加混合；混合后与氯化钙、亮氨酸、羧甲基纤维素钠等量递加混合；再与磷霉素氨丁三醇进行混合，包装，即得。
实施例2
干混悬剂由如下重量百分比的物质组成：
制备方法：利那洛肽和甘露醇、黄原胶、二氧化钛、柠檬酸钠和一水合柠檬酸钠等量递加混合为（1）；磷霉素氨丁三醇与三氯蔗糖、交联羧甲基纤维素钠、草莓香精混合为（2）；将（1）与（2）混合后包装，即得。
实施例3
干混悬剂由如下重量百分比的物质组成：
制备方法：利那洛肽与山梨醇、二氧化钛、黄原胶、亮氨酸等量递加混合为（1）；磷霉素氨丁三醇和柠檬酸钠、三氯蔗糖混合为（2）；将（1）与（2）混合后进行包装，即得。
实施例4
干混悬剂由如下重量百分比的物质组成：
制备方法：利那洛肽和山梨醇、二氧化钛、黄原胶、甲硫氨酸等量递加混合为（1）；磷霉素氨丁三醇与甘露醇、柠檬酸钠和三氯蔗糖混合为（2）；将（1）与（2）混合后进行包装，即得。
实施例5
干混悬剂由如下重量百分比的物质组成：
制备方法：将利那洛肽和磷霉素氨丁三醇粉碎过100目筛；利那洛肽和山梨醇等量递加混合；混合后与氯化钙、羧甲基纤维素钠等量递加混合；再与磷霉素氨丁三醇进行混合，包装，即得。
实施例6
干混悬剂由如下重量百分比的物质组成：
制备方法：将利那洛肽和磷霉素氨丁三醇粉碎过100目筛；利那洛肽和山梨醇等量递加混合；混合后与亮氨酸、羧甲基纤维素钠等量递加混合；再与磷霉素氨丁三醇进行混合，包装，即得。
实施例7
干混悬剂由如下重量百分比的物质组成：
制备方法：利那洛肽和山梨醇、二氧化钛、黄原胶、甲硫氨酸等量递加混合为（1）；磷霉素氨丁三醇与柠檬酸钠和三氯蔗糖混合为（2）；将（1）与（2）混合后进行包装，即得。
实施例8
干混悬剂由如下重量百分比的物质组成：
制备方法：利那洛肽和二氧化钛、黄原胶、甲硫氨酸等量递加混合为（1）；磷霉素氨丁三醇与甘露醇、柠檬酸钠和三氯蔗糖混合为（2）；将（1）与（2）混合后进行包装，即得。
实施例9 稳定性试验
将实施例1-6样品在40℃/75％RH 放置1个月，以考察其含量情况。对照利那洛肽胶囊的制备，参考专利CN 109010254实施例制备得到利那洛肽胶囊。
实施例10 干混悬剂增加小鼠肠转运
为了测定该组合物是否增加了胃肠转运率，使用鼠科肠转运（GIT）测定法检测实施例1-4及实施例7-8制备的干混悬剂和对照药物（利那洛肽胶囊）。试验过程中，在给予小鼠被检药物以后，给予小鼠可以在胃肠道中明显地显现的炭。测量炭移动的距离并表示为结肠总长度的百分比。
在用组合物或对照缓冲液治疗前，小鼠被禁食11到15小时，自由饮水。在给予口服剂量5%活性碳7分钟以前，口服给予1µg/kg-lmg/kg组合物的缓冲液（20mMTris，pH7.5）。在给予活性碳剂量以前，对照小鼠只给予缓冲液。15分钟以后处死小鼠，解剖从胃到盲肠那段肠。测量每只动物的肠的总长以及从胃到炭前端的移动距离，结果表示为炭经过肠占总长度百分比。所有的结果以8只小鼠的平均值±标准差表示。比较给予组合物的小鼠和只给予溶媒的小鼠的炭移动距离，P<0.05认为统计学上差异显著。P值利用假定不等方差的双边T-检验计算。
测定结果如表1所示：
表1
注：*代表与实施例4相比P<0.05。
如表1所示，实施例1-4制备的干混悬组合物在这个模型中能增加且具有较高的胃肠的转运率（优于对照药物），由实施例4与实施例7和实施例8的数据对比可以看出，山梨醇和甘露醇组合使用显著提高胃肠的转运率，协同增效作用明显。
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。
Claims (9)
1.一种干混悬药物组合物，其特征在于，由如下重量百分比的组分构成：利那洛肽0.005-0.02%、磷霉素氨丁三醇30-60%、填充剂30-60%、助悬剂0.5-2.0%、崩解剂0.5-3.0%、稳定剂0.3-1.5%、矫味剂0.02-2.0%、着色剂0.5-3.0%、pH调节剂0.1-3.0%。
2.根据权利要求1所述干混悬药物组合物，其特征在于，所述填充剂为乳糖、甘露醇、麦芽糖醇、山梨醇、淀粉水解寡糖中的一种或几种。
3.根据权利要求1所述干混悬药物组合物，其特征在于，所述助悬剂为黄原胶、聚乙烯吡咯烷酮、羧甲基纤维素钠、明胶、羟丙基纤维素、羟丙甲基纤维素中的一种或几种。
4.根据权利要求1所述干混悬药物组合物，其特征在于，所述崩解剂为低取代的羟丙甲基纤维素、交联羧甲基纤维素钠、交联聚维酮、羧甲基淀粉钠中的一种或几种。
5.根据权利要求1所述干混悬药物组合物，其特征在于，所述稳定剂为亮氨酸、甲硫氨酸、氯化钙、精氨酸中的一种或几种。
6.根据权利要求1所述干混悬药物组合物，其特征在于，所述矫味剂为甜味剂和/或芳香剂；甜味剂为阿斯巴甜、甜菊糖苷、糖精、糖精钠、三氯蔗糖中一种或几种；芳香剂为甜橙香精、柠檬香精、橘子香精、草莓香精中一种或几种。
7.根据权利要求1所述干混悬药物组合物，其特征在于，所述着色剂为二氧化钛。
8.根据权利要求1所述干混悬药物组合物，其特征在于，所述pH调节剂为柠檬酸、柠檬酸钠、一水合柠檬酸、柠檬酸二氢钠中的一种或几种。
9.权利要求1所述干混悬药物组合物的制备方法，其特征在于，按照如下步骤进行：
（1）将原料分别粉碎过80-160目筛；
（2）将利那洛肽、磷霉素氨丁三醇、填充剂、助悬剂、崩解剂、稳定剂、pH调节剂、着色剂采用等量递加的方式，混合均匀，得混和粉末；
（3）取步骤（2）制得的混和粉末与矫味剂混合，包装，制成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310923783.XA CN116672309A (zh) | 2023-07-26 | 2023-07-26 | 干混悬药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310923783.XA CN116672309A (zh) | 2023-07-26 | 2023-07-26 | 干混悬药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116672309A true CN116672309A (zh) | 2023-09-01 |
Family
ID=87789423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310923783.XA Pending CN116672309A (zh) | 2023-07-26 | 2023-07-26 | 干混悬药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116672309A (zh) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180008547A1 (en) * | 2015-02-02 | 2018-01-11 | Aurobindo Pharma Ltd | Stable Compositions comprising Linaclotide |
| CN108904808A (zh) * | 2018-08-15 | 2018-11-30 | 西安力邦医药科技有限责任公司 | 一种治疗便秘的药物组合物及其应用 |
| US20210254056A1 (en) * | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| CN113616616A (zh) * | 2021-09-07 | 2021-11-09 | 四川国为制药有限公司 | 一种利那洛肽胶囊制剂及其制备方法 |
| CN114668711A (zh) * | 2008-08-15 | 2022-06-28 | 硬木药品公司 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
| CN115105582A (zh) * | 2021-03-17 | 2022-09-27 | 江苏豪森药业集团有限公司 | 一种含利那洛肽或其盐的药物组合物及其制备方法 |
| CN115154582A (zh) * | 2022-08-24 | 2022-10-11 | 北京双鹤润创科技有限公司 | 一种含利那洛肽的药物组合物、制备方法及其瓶装胶囊制剂 |
| US20230001128A1 (en) * | 2019-11-25 | 2023-01-05 | Gary Stephen Shuster | Aerosolization systems, methods, and apparatuses |
| CN116098864A (zh) * | 2023-04-11 | 2023-05-12 | 北京普诺旺康医药科技有限公司 | 一种利那洛肽干混悬剂及其制备方法 |
-
2023
- 2023-07-26 CN CN202310923783.XA patent/CN116672309A/zh active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114668711A (zh) * | 2008-08-15 | 2022-06-28 | 硬木药品公司 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
| US20180008547A1 (en) * | 2015-02-02 | 2018-01-11 | Aurobindo Pharma Ltd | Stable Compositions comprising Linaclotide |
| US20210254056A1 (en) * | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| CN108904808A (zh) * | 2018-08-15 | 2018-11-30 | 西安力邦医药科技有限责任公司 | 一种治疗便秘的药物组合物及其应用 |
| US20230001128A1 (en) * | 2019-11-25 | 2023-01-05 | Gary Stephen Shuster | Aerosolization systems, methods, and apparatuses |
| CN115105582A (zh) * | 2021-03-17 | 2022-09-27 | 江苏豪森药业集团有限公司 | 一种含利那洛肽或其盐的药物组合物及其制备方法 |
| CN113616616A (zh) * | 2021-09-07 | 2021-11-09 | 四川国为制药有限公司 | 一种利那洛肽胶囊制剂及其制备方法 |
| CN115154582A (zh) * | 2022-08-24 | 2022-10-11 | 北京双鹤润创科技有限公司 | 一种含利那洛肽的药物组合物、制备方法及其瓶装胶囊制剂 |
| CN116098864A (zh) * | 2023-04-11 | 2023-05-12 | 北京普诺旺康医药科技有限公司 | 一种利那洛肽干混悬剂及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| GUADALUPE MARTÍNEZ等: ""Effect of fosfomycin, Cynara scolymusextract, deoxynivalenol and theircombinations on intestinal health of weaned piglets"", 《ANIMAL NUTRITION》, pages 386 - 395 * |
| 刘正印等: ""复安欣（磷霉素氨丁三醇）治疗肠道和泌尿系统感染临床观察"", 《中国新药杂志》, vol. 9, no. 1, pages 596 - 597 * |
| 王艳丽等: "《现代外科疾病诊疗》", 中国海洋大学出版社, pages: 152 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6764959B2 (ja) | 医薬組成物 | |
| US20060127480A1 (en) | Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof | |
| AU2011279158B2 (en) | Method and formulations for treating sialic acid deficiencies | |
| PT86212B (pt) | Processo para a preparacao de uma formulacao galenica | |
| AU2002302147B2 (en) | Pharmaceutical composition | |
| CN107693515B (zh) | 含碱化剂和艾曲泊帕的药物组合物及其用途 | |
| KR101136655B1 (ko) | 레보타이록신 나트륨을 포함하는 제약 제제 | |
| WO2006109737A1 (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 | |
| PT1594500E (pt) | Tratamento para doenças bacterianas dos órgãos respiratórios por aplicação local de fluoroquinolonas | |
| CN116098864B (zh) | 一种利那洛肽干混悬剂及其制备方法 | |
| JP3899522B2 (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 | |
| CN116672309A (zh) | 干混悬药物组合物 | |
| KR102413426B1 (ko) | 나라트립탄을 포함하는 구강용해 필름 제형 | |
| BG60851B1 (bg) | Таблетка, съдържаща натриев 2-меркаптоетансулфонат (месна), като активно вещество и метод за получаването й | |
| KR20060010838A (ko) | 아목시실린 및 클라블라네이트를 포함하는 약제학적 제형 | |
| KR100850863B1 (ko) | 아세틸-엘-카르니틴 함유 속용성 제제 | |
| WO2018124283A1 (ja) | 医薬組成物 | |
| CN111744018A (zh) | 一种盐酸氨基葡萄糖药物制剂 | |
| CN109675057A (zh) | 一种含有链霉蛋白酶的固体制剂及其制备方法 | |
| WO2021194446A1 (en) | A sachet formulation comprising metformin and dapagliflozin | |
| JP2023164069A (ja) | ゾニサミド含有口腔内崩壊錠 | |
| JP2006316051A (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |